Showing 27,281 - 27,300 results of 55,104 for search '(( a ((mean decrease) OR (linear decrease)) ) OR ( a ((greater decrease) OR (largest decrease)) ))', query time: 0.84s Refine Results
  1. 27281

    Table 1_Characteristics and trends of unintentional injuries among children and adolescents in Kunshan, China: a hospital-based retrospective study, 2018–2023.docx by Li Shen (110858)

    Published 2025
    “…The refined ARIMA(1,1,2) (0,1,1)[12] model, excluding pandemic effects, achieved a mean absolute percentage error of 6.46% while revealing seasonal patterns and predicting a slight downward trend for 2024–2026.…”
  2. 27282

    Table_1_Relationship between triglyceride-glucose index and cognitive function among community-dwelling older adults: a population-based cohort study.docx by Weimin Bai (7005770)

    Published 2024
    “…</p>Results<p>The study included 2,959 participants, with a mean age of 71.2 ± 5.4 years, 49.8% of whom were female. …”
  3. 27283

    Data Sheet 1_The effect of Traditional Chinese Medicine on patients undergoing targeted therapy for primary liver cancer: a systematic review and meta-analysis.docx by Hongting Yan (13242201)

    Published 2025
    “…</p>Methods<p>We conducted a comprehensive search of databases. The search scope covered the period from the establishment of the databases to April 2025. …”
  4. 27284

    Table_2_Relationship between triglyceride-glucose index and cognitive function among community-dwelling older adults: a population-based cohort study.docx by Weimin Bai (7005770)

    Published 2024
    “…</p>Results<p>The study included 2,959 participants, with a mean age of 71.2 ± 5.4 years, 49.8% of whom were female. …”
  5. 27285

    Using a Partial Sum Method and GPS Tracking Data to Identify Area Restricted Search by Artisanal Fishers at Moored Fish Aggregating Devices in the Commonwealth of Dominica by Michael Alvard (688759)

    Published 2015
    “…These patches can be identified behaviorally when a forager shifts from travel to area restricted search, identified by a decrease in speed and an increase in sinuosity of movement. …”
  6. 27286

    Table_1_Associations of rumination, behavioral activation, and perceived reward with mothers’ postpartum depression during the COVID-19 pandemic: a cross-sectional study.DOCX by Miki Matsunaga (17822822)

    Published 2024
    “…A questionnaire was administered to 475 postpartum women (Age: Mean = 30.74 years, SD = 5.02) within 1 year of childbirth using an Internet survey. …”
  7. 27287

    <i>A</i>. <i>americanum</i> tick PI-rTSP induce expression of chemokines <i>in vivo</i>, AI-rTSPs suppresses. by Mariam Bakshi (7962230)

    Published 2019
    “…<p>Relative transcript abundance of chemokines in paws that were injected with low dose individual (A, B, C, D and E) or with cocktail PI-rTSP or Carrageenan followed by individual or cocktail AI-rTSP (F, G, H, I). …”
  8. 27288

    The mRNA expression of <i>ARID1A</i> in human primary gastric cancer surgical specimens was evaluated by real-time quantitative PCR. by Dan-dan Wang (200585)

    Published 2013
    “…<p>The relative mRNA expression of <i>ARID1A</i> was significantly decreased in gastric cancer tissues compared with the matched adjacent nontumorous tissues (n = 66, <i>P</i> = 0.0029). …”
  9. 27289

    Table_1_Psychological wellbeing among carers of children and adolescents with physical disabilities in North-Eastern Tanzania—a cross-sectional survey study.docx by Elia Asanterabi Swai (15337336)

    Published 2024
    “…The lack of structured mechanisms to address this psychological burden poses a considerable threat to the wellbeing of both carers and the children with disabilities under their care. …”
  10. 27290

    Table 1_Impact of dual residual risk of cholesterol and inflammation on adult male sex hormones: a cross-sectional study from NHANES.docx by Yang Zhou (65942)

    Published 2025
    “…Notably, hs-CRP exhibited a non-linear correlation with TT, SHBG, and FT, with distinct inflection points. …”
  11. 27291
  12. 27292

    Data_Sheet_1_Serum Anti-Müllerian Hormone Is Significantly Altered by Downregulation With Daily Gonadotropin-Releasing Hormone Agonist: A Prospective Cohort Study.docx by Panagiotis Drakopoulos (5444162)

    Published 2019
    “…</p><p>Results: Under GnRH agonist treatment, serum AMH was significantly decreased vs. baseline on day 7 (mean change from baseline: −0.265 ng/mL; 95% confidence interval [CI], −0.395 to −0.135 ng/mL; p < 0.001). …”
  13. 27293

    DataSheet1_Pingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson’s Disease: A Randomized, Double-Blind, Placebo-Controlled Study.DOCX by Si-Chun Gu (12135735)

    Published 2022
    “…</p><p>Results: Generalized estimating equation analyses revealed that the PCG group had significantly better improvement in UPDRS-III score at T1, T2, and T3 [time-by-group interaction, T1: β, −0.92 (95% CI, −1.59–−0.25; p = 0.01); T2: β, −2.08 (95% CI, −2.90–−1.27; p < 0.001); T3: β, −4.54 (95% CI, −5.37–−3.71; p < 0.001))]. The PCG group showed a greater decrease (rate of disease change) in the total UPDRS score between T0 and T2 [−2.23 (95% CI, −2.72–−1.73; p < 0.001) points per week vs. −0.21 (95% CI, −0.80–0.39; p = 0.50) points per week in the placebo group, p < 0.001]. …”
  14. 27294

    Differences in FA between the OO group and the NW group using both TBSS analysis (Figure 3a) and VBA method (Figure 3b). by Baohui Lou (639539)

    Published 2014
    “…<p>(<b>3a</b>) Green represents mean FA skeleton of all participants, while red represents regions with significantly decreased FA in the OO group (<i>P</i><0.05, corrected for multiple comparisons). …”
  15. 27295

    Changes in disease burden in Poland between 1990–2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017 by Maria Gańczak (8519883)

    Published 2020
    “…DALYs due to non-communicable diseases (NCDs) decreased slightly (2.0%; 0.1–4.6). In 2017, Poland performed better than CE as a whole (ranked fourth for YLLs, sixth for YLDs, and fifth for DALYs) and achieved greater reductions in YLLs and DALYs than most CE countries. …”
  16. 27296

    Growth factors expression and ultrastructural morphology after application of low-level laser and natural latex protein on a sciatic nerve crush-type injury by Fernando José Dias (3174455)

    Published 2019
    “…Med:19.4%area). At week 8, a general reduction of VEGF expression was noted, remaining higher in F1 (Med:35.1; Q1.30.6; Q3.39.6%area) and LLLT&F1 (Med:18.5; Q1:16; Q3:25%area). …”
  17. 27297

    Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2019
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
  18. 27298

    Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2019
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
  19. 27299

    Data_Sheet_1_Body Weight Variability Increases Dementia Risk Among Older Adults: A Nationwide Population-Based Cohort Study.docx by Eun Roh (1526662)

    Published 2020
    “…</p><p>Methods: We performed a retrospective elderly cohort study from 19,987 participants with mean age 73 years old in the Korean National Health Insurance Service. …”
  20. 27300

    Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2022
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”